Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03618537 · ClinicalTrials.gov registry record · Phase 2
Ixazomib Maintenance Study in Patients With AL Amyloidosis
A Phase 2 study of AL Amyloidosis, sponsored by Memorial Sloan Kettering Cancer Center.
- Active
- Registry status
- Phase 2
- Development phase
- 17
- Enrollment target
- 8
- Study locations
NCT03618537: Active Phase 2 study of AL Amyloidosis, sponsored by Memorial Sloan Kettering Cancer Center.
NCT03618537 is a Phase 2 study of AL Amyloidosis that is active but no longer recruiting, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 17 participants, below the 423-participant average among 15 other AL Amyloidosis trials with a reported enrollment target (96% lower). The trial reports 8 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03618537, a Phase 2 study of AL Amyloidosis, is active but no longer recruiting, sponsored by Memorial Sloan Kettering Cancer Center.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 17 participants
- Enrollment target
- 8
- Study locations
Study Summary
The purpose of this study is to learn if Ixazomib maintenance treatment (chemotherapy) works to control the disease. Through this study, the investigators hope to learn more about ways to prevent or delay relapse of AL Amyloidosis.
Primary Outcome
(EFS includes organ progression, next antiplasma cell directed therapy or death)
Conditions Studied
Interventions
- DRUG Dexamethasone
- DRUG Ixazomib
Study Locations (8)
New York
- Memorial Sloan Kettering Commack - Commack
- Memorial Sloan Kettering Westchester - Harrison
- Memorial Sloan Kettering Cancer Center - New York
- Memorial Sloan Kettering Nassau - Uniondale
New Jersey
- Memorial Sloan Kettering Basking Ridge - Basking Ridge
- Memorial Sloan Kettering Monmouth - Middletown
- Memorial Sloan Kettering Bergen - Montvale
Massachusetts
- Tufts Medical Center - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 17 participants |
| Start Date | 2018-08-02 |
| Est. Completion | 2026-08 |
| Phase | Phase 2 |
What the registry record for NCT03618537 still lists
NCT03618537 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 17 participants, a relatively small participant target, below the 423-participant average among 15 other AL Amyloidosis trials with a reported enrollment target (96% lower).
The record links to 1 condition, with AL Amyloidosis appearing as the primary indexed condition, and to 2 interventions - of which Dexamethasone is the first listed.
NCT03618537 lists 8 locations in 3 states (New York, New Jersey, Massachusetts).
Frequently Asked Questions
What is clinical trial NCT03618537 about?
NCT03618537 is a clinical study titled "Ixazomib Maintenance Study in Patients With AL Amyloidosis". The purpose of this study is to learn if Ixazomib maintenance treatment (chemotherapy) works to control the disease. Through this study, the investigators hope to learn more about ways to prevent or delay relapse of AL Amyloidosis.
What is the current status of trial NCT03618537?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 17 participants. The study started on 2018-08-02. Estimated completion is 2026-08.
What conditions does trial NCT03618537 study?
This clinical trial studies the following conditions: AL Amyloidosis.
What interventions are being tested in trial NCT03618537?
The interventions under investigation include: Dexamethasone (DRUG), Ixazomib (DRUG).
Who is sponsoring clinical trial NCT03618537?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03618537 being conducted?
This trial has 8 study locations across Massachusetts, New Jersey, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for AL Amyloidosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03618537's enrollment target sits among peer trials
17 14th of 15 higher than 2 of 15 other AL Amyloidosis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other AL Amyloidosis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Daratumumab Maintenance Therapy for Improving Survival in Patients With Light Chain Amyloidosis, EMILIA Trial
RECRUITING · Phase 2
-
Daratumumab, Pomalidomide, and Dexamethasone (DPd) in Relapsed/Refractory Light Chain Amyloidosis Patients Previously Exposed to Daratumumab
ACTIVE NOT RECRUITING · Phase 2
-
Siltuximab to Decrease Symptom Burden After Autologous Stem Cell Transplantation for Patients With Multiple Myeloma and AL Amyloidosis
ACTIVE NOT RECRUITING · Phase 2
-
Bendamustine and Dexamethasone in Patients With Relapsed AL Amyloidosis
COMPLETED · Phase 2
-
Ohio State University Multiple Myeloma and Amyloidosis Data Registry and Sample Resource
RECRUITING
-
Phase 1/2a Study of Belantamab Mafodotin in Relapsed or Refractory AL Amyloidosis
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02090140 · 17 participants · NA
Microfracture Versus Adipose Derived Stem Cells for the Treatment of Articular Cartilage Defects
- NCT03317860 · 17 participants · NA
Improving Measurement and Treatment of Post-stroke Neglect
- NCT04356469 · 17 participants · Phase 2
TCR Alpha Beta T-cell Depleted Haploidentical HCT in the Treatment of Non-Malignant Hematological Disorders in Children
- NCT04414046 · 17 participants · Phase 2
TCR Alpha Beta T-cell Depleted Haploidentical HCT in the Treatment of Primary Immunodeficiency and Inherited Metabolic Disorders in Children
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI